Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results

References

• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, Bakris GL; ASoHW Group. Combination therapy in hypertension. J. Am. Soc. Hypertens.4(1), 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson JA, Davis JO, Gotshall RW et al. Evidence for an intrarenal β receptor in control of renin release. Am. J. Physiol.230(2), 410–418 (1976).
   PubMed Web of Science ®Google Scholar
• Safar ME, Weiss YA, Corvol PL, Menard JE, London GM, Milliez PL. Anti-hypertensive adrenergic-blocking agents: effects on sodium balance, the renin–angiotensin system and haemodynamics. Clin. Sci. Mol. Med. Suppl.2, 93S–95S (1975).
   Google Scholar
• Weber MA, Case DB, Baer L et al. Renin and aldosterone suppression in the antihypertensive action of clonidine. Am. J. Cardiol.38(6), 825–830 (1976).
   PubMed Web of Science ®Google Scholar
• Blumenfeld JD, Sealey JE, Mann SJ et al. β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin–angiotensin–aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens.12(5), 451–459 (1999).
   PubMed Web of Science ®Google Scholar
• Fernandez SF, Huang MH, Davidson BA, Knight PR 3rd, Izzo JL Jr. Modulation of angiotensin II responses in sympathetic neurons by cytosolic calcium. Hypertension41, 56–63 (2003).
   PubMedGoogle Scholar
• Fernandez SF, Huang MH, Davidson BA, Knight PR 3rd, Izzo JL Jr. Mechanisms of angiotensin II-mediated decreases in intraneuronal Ca2+ in calcium-loaded stellate ganglion neurons. Hypertension45(2), 276–282 (2005).
   PubMedGoogle Scholar
• Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am. J. Hypertens.22(1), 112–121 (2009).
   PubMed Web of Science ®Google Scholar
• Stanton AV, Dicker P, O’Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am. J. Hypertens.22(9), 954–957 (2009).
   PubMed Web of Science ®Google Scholar
• Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J. Hypertens.20(4), 771–777 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J.12, 1462–1536 (2007).
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure18(6), 308–347 (2009).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J. Clin. Hypertens.9, 678–686 (2010).
   Google Scholar
• Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J, Tou CK; AMAZE. Antihypertensive efficacy of candesartan–lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J. Clin. Hypertens.6(9), 485–493 (2004).
   PubMedGoogle Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349(20), 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation119(4), 530–537 (2009).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail.1, 17–24 (2008).
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Implications of species difference for clinical investigation: studies on the renin–angiotensin system. Hypertension (1 Pt 2), 150–154 (2000).
   PubMedGoogle Scholar
• Bohlender J, Fukamizu A, Lippoldt A et al. High human renin hypertension in transgenic rats. Hypertension29(1 Pt 2), 428–434 (1997).
   PubMed Web of Science ®Google Scholar
• Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol. Rev.15(5), 242–256 (1997).
   Google Scholar
• Delea TE, Sofrygin O, Palmer JL et al. Cost–effectiveness of aliskiren in Type 2 diabetes, hypertension, and albuminuria. J. Am. Soc. Nephrol.10, 2205–2213 (2009).
   Google Scholar
• Persson F, Lewis JB, Lewis EJ et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with Type 2 diabetes and nephropathy. Diabetes Care33(11), 2304–2309 (2010).
   PubMed Web of Science ®Google Scholar
• Lee HY, Oh BH. Cardio–renal protection with aliskiren, a direct renin inhibitor, in the Aspire Higher program. Expert Rev. Cardiovasc. Ther.7(3), 251–257 (2009).
   PubMedGoogle Scholar
• Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant.24(5), 1663–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115(1), 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Verma A, Desai A et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension55(2), 241–248 (2010).
   PubMedGoogle Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2004 secondary prevention trials. Hypertens. Res.28(5), 385–407 (2003).
   Google Scholar
• Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA285(21), 2719–2728 (2001).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet375(9721), 1173–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Purkayastha D, Hall D, Hilkert RJ. Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. J. Hum. Hypertens.24(6), 403–409 (2010).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation113(9), 1213–1225 (2006).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens.9(10), 742–750 (2007).
   PubMedGoogle Scholar
• Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr. Med. Res. Opin.25(4), 951–959 (2009).
   PubMed Web of Science ®Google Scholar
• Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the Calcium Channel Blocker Amlodipine as an Initial Treatment Strategy for Hypertension Control (ACCELERATE): a randomised, parallel-group trial. Lancet377(9762), 278–279 (2011).
   PubMedGoogle Scholar
• Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension49(5), 1047–1055 (2011).
   Google Scholar
• Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril–Felodipine ER Factorial Study Group. Am. J. Cardiol.79(4), 431–435 (1997).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens.11(9), 475–482 (2009).
   PubMed Web of Science ®Google Scholar